Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2023 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Transition of Chief Financial Officer

WALTHAM, Mass., June 29, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
June 06, 2023 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors

WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
June 01, 2023 16:10 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
June 01, 2023 16:05 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Closing of Public Offering

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
June 01, 2023 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics to Participate in the Jefferies Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
May 26, 2023 00:37 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Pricing of $140 Million Public Offering

WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
May 25, 2023 16:06 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Announces Launch of Proposed Public Offering

WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
May 24, 2023 16:13 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors

WALTHAM, Mass., May 24, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX) (TScan), a clinical-stage biopharmaceutical company focused on the development of T cell receptor...
May 17, 2023 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting

Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation Company to host a virtual KOL event featuring Monzr M. Al Malki, M.D., to...
May 10, 2023 07:00 ET | Source: TScan Therapeutics, Inc.

TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Entered into partnership with Amgen to identify novel targets in Crohn’s disease; TScan to receive $30 million upfront Enrolled patients in all three arms of Phase 1 hematologic malignancies study;...